Limited Access: Real-World Cellular Therapy Experience in Aggressive Lymphomas and the Underrepresentation of Black Patients
Document Type
Conference Proceeding
Publication Date
4-24-2025
Publication Title
International Journal of Cancer Care and Delivery
Abstract
Background: Cellular therapy comprises Chimeric Antigen Receptor (CAR) and Bispecific T-cell Engager (BiTE) therapy. As of June 2024, six CAR-T cell therapies have been approved, demonstrating efficacy in patients with B-cell malignancies and multiple myeloma (1). Still, use of CAR-T has been limited for several reasons including toxicity, cost, patient hesitation, and absence of caregiver support (2). We assess real-life outcomes and referral/treatment patterns of patients at our community center.
Volume
5
Issue
Suppl 1
First Page
S51
Last Page
S52
Recommended Citation
Idogun P, Jaiyesimi I, Ezekwudo D. Limited access: real-world cellular therapy experience in aggressive lymphomas and the underrepresentation of Black patients. Int J Cancer Care Deliv. 2025 Apr 24; 5(Suppl 1):S51-S52. doi:10.53876/001aa.129521
DOI
10.53876/001aa.129521
Comments
Summit on Cancer Health Disparities (SCHD25), April 25-27, 2025, Seattle, WA